U.S. markets closed
  • S&P Futures

    4,406.50
    +17.00 (+0.39%)
     
  • Dow Futures

    34,958.00
    +126.00 (+0.36%)
     
  • Nasdaq Futures

    15,002.50
    +46.75 (+0.31%)
     
  • Russell 2000 Futures

    2,234.30
    +12.70 (+0.57%)
     
  • Crude Oil

    73.85
    -0.10 (-0.14%)
     
  • Gold

    1,817.30
    +0.10 (+0.01%)
     
  • Silver

    25.55
    +0.00 (+0.01%)
     
  • EUR/USD

    1.1869
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • Vix

    18.24
    +0.54 (+3.05%)
     
  • GBP/USD

    1.3901
    -0.0005 (-0.04%)
     
  • USD/JPY

    109.7200
    +0.1050 (+0.10%)
     
  • BTC-USD

    40,383.78
    -1,436.62 (-3.44%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.81 (-1.80%)
     

Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study

·2 min read
  • Theravance Biopharma Inc (NASDAQ: TBPH) has announced top-line results from its Phase 2 study evaluating nezulcitinib for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.

  • Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase (JAK) inhibitor.

  • No statistically significant difference in Respiratory Failure-Free Days (RFDs) from randomization through Day 28 between nezulcitinib and placebo was reported.

  • Nezulcitinib demonstrated a favorable trend in improvement when compared to placebo for 28-day all-cause mortality (total number of deaths: 6 vs. 13) and time to recovery (median: 10 vs. 11 days).

  • In patients with CRP of more than 150 mg/L (n=171), there was an improvement in those treated with nezulcitinib compared to placebo.

  • 28-day all-cause mortality (total number of deaths: 1 vs. 9) and time to recovery (median: 10 vs. 11 days).

  • In patients with CRP >150 mg/L (n=30), there was no difference in time to recovery or 28-day all-cause mortality between those treated with nezulcitinib or placebo.

  • Nezulcitinib was well-tolerated; adverse events and serious adverse events occurred in 34.0% and 9.7% of patients treated with nezulcitinib, 41.2%, and 15.7% treated with placebo, respectively.

  • Adverse events of liver abnormalities or disease occurred in 9.7% and 7.8% of patients treated with nezulcitinib and placebo, respectively.

  • Severe infections and venous thromboembolism occurred in 1.0% and none of the patients treated with nezulcitinib, and 2.0% and 4.9% in patients treated with placebo, respectively.

  • The Company will share these results with FDA and other regulatory agencies to seek input on protocols further to study nezulcitinib in acute hyper inflammation in the lung.

  • The Company will hold a conference call today at 8 am E.T.

  • Price Action: TBPH shares are down 6.39% at $16.40 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.